Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 147 entries
Sorted by: Best Match Show Resources per page
A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab

stem intervention research

[No authors listed]
GSID: PxGDPfBZ_bsJ
MH Jeong, YK Ahn, JC Park, BH Ahn… - Journal of Korean …, 2001 - synapse.koreamed.org

A 61-yr-old male patient presented with severe chest pain with cardiogenic shock due to an extensive anterolateral myocardial infarction. Two-dimensional echocardiogram showed severe left ventricular systolic dysfunction (ejection fraction= 17%). Emergent coronary angiogram obtained immediately after placing temporary pacing...

Cite
Jeong, M. H., Ahn, Y. K., Park, J. C., Ahn, B. H., Na, K. J., Kim, N. H., ... & Kang, J. C. (2001). A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab. Journal of Korean Medical Science, 16(4), 509-511.
Jeong, Myung Ho, et al. "A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab." Journal of Korean Medical Science 16.4 (2001): 509-511.
Copy Download .nbib Format: MLA
Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome.

International journal of cardiology. Heart & vessels

Shakoor MT, Ayub S, Dhakam S.
PMID: 29450173
Int J Cardiol Heart Vessel. 2014 Mar 19;3:64-67. doi: 10.1016/j.ijchv.2014.03.007. eCollection 2014 Jun.

BACKGROUND: Abciximab reduces major adverse cardiac events in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Standard protocol is intravenous abciximab bolus during PCI plus abciximab infusion for 12-18 h post pPCI. Intracoronary (IC) abciximab...

Cite
Shakoor MT, Ayub S, Dhakam S. Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome. Int J Cardiol Heart Vessel. 2014;3:64-67doi: 10.1016/j.ijchv.2014.03.007.
Shakoor, M. T., Ayub, S., & Dhakam, S. (2014). Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome. International journal of cardiology. Heart & vessels, 364-67. https://doi.org/10.1016/j.ijchv.2014.03.007
Shakoor, Muhammad Tariq, et al. "Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome." International journal of cardiology. Heart & vessels vol. 3 (2014): 64-67. doi: https://doi.org/10.1016/j.ijchv.2014.03.007
Shakoor MT, Ayub S, Dhakam S. Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome. Int J Cardiol Heart Vessel. 2014 Mar 19;3:64-67. doi: 10.1016/j.ijchv.2014.03.007. eCollection 2014 Jun. PMID: 29450173; PMCID: PMC5801446.
Copy Download .nbib Format: NLM
Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, Gibson CM, Stone GW.
PMID: 23764966
EuroIntervention. 2013 Jun 14; Epub 2013 Jun 14.

Aims: To determine the relation between thrombus aspiration (TA) and/or intra-lesion (IL) abciximab with pre-stent Thrombolysis in Myocardial Infarction (TIMI) flow grade and infarct size (IS) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)....

Cite
Brener SJ, Dambrink JH, Maehara A, et al. Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention. 2013;
Brener, S. J., Dambrink, J. H., Maehara, A., Chowdhary, S., Gershlick, A. H., Genereux, P., Koolen, J., Mehran, R., Fahy, M., Gibson, C. M., & Stone, G. W. (2013). Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, .
Brener, Sorin J, et al. "Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. (2013).
Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, Gibson CM, Stone GW. Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention. 2013 Jun 14; Epub 2013 Jun 14. PMID: 23764966.
Copy Download .nbib Format: NLM
Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients.

JRSM cardiovascular disease

Rathod KS, Antoniou S, Avari P, Ding N, Wright P, Knight C, Jain AK, Mathur A, Smith EJ, Weerackody R, Wragg A, Jones DA.
PMID: 29051816
JRSM Cardiovasc Dis. 2017 Oct 05;6:2048004017734431. doi: 10.1177/2048004017734431. eCollection 2017.

INTRODUCTION: Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. There are few studies directly comparing these agents. The aim of this study was to assess whether eptifibatide...

Cite
Rathod KS, Antoniou S, Avari P, et al. Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients. JRSM Cardiovasc Dis. 2017;6:2048004017734431doi: 10.1177/2048004017734431.
Rathod, K. S., Antoniou, S., Avari, P., Ding, N., Wright, P., Knight, C., Jain, A. K., Mathur, A., Smith, E. J., Weerackody, R., Wragg, A., & Jones, D. A. (2017). Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients. JRSM cardiovascular disease, 62048004017734431. https://doi.org/10.1177/2048004017734431
Rathod, K S, et al. "Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients." JRSM cardiovascular disease vol. 6 (2017): 2048004017734431. doi: https://doi.org/10.1177/2048004017734431
Rathod KS, Antoniou S, Avari P, Ding N, Wright P, Knight C, Jain AK, Mathur A, Smith EJ, Weerackody R, Wragg A, Jones DA. Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients. JRSM Cardiovasc Dis. 2017 Oct 05;6:2048004017734431. doi: 10.1177/2048004017734431. eCollection 2017. PMID: 29051816; PMCID: PMC5637964.
Copy Download .nbib Format: NLM
Combination Enoxaparin and Abciximab During Percutaneous Coronary Intervention: A New Standard of Care?.

Current interventional cardiology reports

Kereiakes DJ, Grines C, Fry E, Esente A, Barr L, Matthai W, Shimshak T, Broderick T, Cohen M.
PMID: 11096663
Curr Interv Cardiol Rep. 2000 May;2(2):157-164.

Evidence from randomized trials supports the administration of platelet glycoprotein (GP) IIb/IIIa blockade both to patients undergoing percutaneous coronary intervention (PCI) and those presenting with non-ST elevation acute coronary syndromes (ACSs). Similarly, the low molecular weight heparin (LMWH), enoxaparin,...

Cite
Kereiakes DJ, Grines C, Fry E, et al. Combination Enoxaparin and Abciximab During Percutaneous Coronary Intervention: A New Standard of Care?. Curr Interv Cardiol Rep. 2000;2(2):157-164
Kereiakes, D. J., Grines, C., Fry, E., Esente, A., Barr, L., Matthai, W., Shimshak, T., Broderick, T., & Cohen, M. (2000). Combination Enoxaparin and Abciximab During Percutaneous Coronary Intervention: A New Standard of Care?. Current interventional cardiology reports, 2(2), 157-164.
Kereiakes, et al. "Combination Enoxaparin and Abciximab During Percutaneous Coronary Intervention: A New Standard of Care?." Current interventional cardiology reports vol. 2,2 (2000): 157-164.
Kereiakes DJ, Grines C, Fry E, Esente A, Barr L, Matthai W, Shimshak T, Broderick T, Cohen M. Combination Enoxaparin and Abciximab During Percutaneous Coronary Intervention: A New Standard of Care?. Curr Interv Cardiol Rep. 2000 May;2(2):157-164. PMID: 11096663.
Copy Download .nbib Format: NLM
Corrections: Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels.

The New England journal of medicine

[No authors listed]
PMID: 10441795
N Engl J Med. 1999 Aug 12;341(7):548. doi: 10.1056/nejm199908123410726.

No abstract available.

Cite
Corrections: Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels. N Engl J Med. 1999;341(7):548doi: 10.1056/nejm199908123410726.
(1999). Corrections: Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels. The New England journal of medicine, 341(7), 548. https://doi.org/10.1056/nejm199908123410726
"Corrections: Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels." The New England journal of medicine vol. 341,7 (1999): 548. doi: https://doi.org/10.1056/nejm199908123410726
Corrections: Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels. N Engl J Med. 1999 Aug 12;341(7):548. doi: 10.1056/nejm199908123410726. PMID: 10441795.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 11980386
Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses, which has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(1):37-55
Bayes, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(1), 37-55.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,1 (2002): 37-55.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55. PMID: 11980386.
Copy Download .nbib Format: NLM
Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura.

International journal of cardiovascular interventions

Segal OR, Baker CS, Banim S.
PMID: 12431338
Int J Cardiovasc Intervent. 2001 Mar;4(1):35-38. doi: 10.1080/146288401316922670.

The use of the antiplatelet agents abciximab and clopidogrel is now accepted therapy in percutaneous coronary intervention. We present a case in which these agents were used in a patient with idiopathic thrombocytopaenic purpura and a platelet count of...

Cite
Segal OR, Baker CS, Banim S. Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura. Int J Cardiovasc Intervent. 2001;4(1):35-38doi: 10.1080/146288401316922670.
Segal, O. R., Baker, C. S., & Banim, S. (2001). Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura. International journal of cardiovascular interventions, 4(1), 35-38. https://doi.org/10.1080/146288401316922670
Segal, Oliver R, et al. "Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura." International journal of cardiovascular interventions vol. 4,1 (2001): 35-38. doi: https://doi.org/10.1080/146288401316922670
Segal OR, Baker CS, Banim S. Percutaneous coronary intervention with adjunctive abciximab and clopidogrel in a patient with chronic idiopathic thrombocytopaenic purpura. Int J Cardiovasc Intervent. 2001 Mar;4(1):35-38. doi: 10.1080/146288401316922670. PMID: 12431338.
Copy Download .nbib Format: NLM
Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis.

International journal of cardiovascular interventions

Mamtimin H, Rupprecht HJ, Nowak B, Voigtländer T, Darius H, Meyer J.
PMID: 12470368
Int J Cardiovasc Intervent. 2000 Sep;3(3):173-179. doi: 10.1080/14628840050516091.

AIMS: This study evaluated the treatment of early coronary stent thrombosis with intracoronary urokinase or the platelet glycoprotein IIb/IIIa receptor inhibitor ReoPro (abciximab). METHODS AND RESULTS: Seventy-four patients (126 stents) were treated immediately after identification of early (0-30 days)...

Cite
Mamtimin H, Rupprecht HJ, Nowak B, et al. Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis. Int J Cardiovasc Intervent. 2000;3(3):173-179doi: 10.1080/14628840050516091.
Mamtimin, H., Rupprecht, H. J., Nowak, B., Voigtländer, T., Darius, H., & Meyer, J. (2000). Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis. International journal of cardiovascular interventions, 3(3), 173-179. https://doi.org/10.1080/14628840050516091
Mamtimin, Hayraet, et al. "Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis." International journal of cardiovascular interventions vol. 3,3 (2000): 173-179. doi: https://doi.org/10.1080/14628840050516091
Mamtimin H, Rupprecht HJ, Nowak B, Voigtländer T, Darius H, Meyer J. Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis. Int J Cardiovasc Intervent. 2000 Sep;3(3):173-179. doi: 10.1080/14628840050516091. PMID: 12470368.
Copy Download .nbib Format: NLM
The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention.

International journal of cardiovascular interventions

Salame MY, More RS, Verheye S, Leimbach ME, King SB, Chronos NA.
PMID: 12623570
Int J Cardiovasc Intervent. 1999;2(4):207-215. doi: 10.1080/acc.2.4.207.215.

Glycoprotein IIb/IIIa receptor inhibitors represent a relatively new therapeutic approach in the field of antiplatelet therapy. Following the development of abciximab a number of small molecule GPIIb/IIIa inhibitors have been introduced such as tirofiban and eptifibatide. In this fast-moving...

Cite
Salame MY, More RS, Verheye S, et al. The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. Int J Cardiovasc Intervent. 1999;2(4):207-215doi: 10.1080/acc.2.4.207.215.
Salame, M. Y., More, R. S., Verheye, S., Leimbach, M. E., King, S. B., & Chronos, N. A. (1999). The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. International journal of cardiovascular interventions, 2(4), 207-215. https://doi.org/10.1080/acc.2.4.207.215
Salame, Mahomed Y, et al. "The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention." International journal of cardiovascular interventions vol. 2,4 (1999): 207-215. doi: https://doi.org/10.1080/acc.2.4.207.215
Salame MY, More RS, Verheye S, Leimbach ME, King SB, Chronos NA. The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. Int J Cardiovasc Intervent. 1999;2(4):207-215. doi: 10.1080/acc.2.4.207.215. PMID: 12623570.
Copy Download .nbib Format: NLM
Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic.

International journal of cardiovascular interventions

Umans VA, Cornel JH, Velthoven SS, Kloeg P, Bartels P, Bronzwaer J.
PMID: 12623572
Int J Cardiovasc Intervent. 1999;2(4):223-230. doi: 10.1080/acc.2.4.223.230.

BACKGROUND: Although balloon angioplasty has assumed an important role in the management of refractory unstable angina (UA), that is, UA that does not respond to conventional therapy, it is limited by complications related to thrombosis and acute coronary occlusion....

Cite
Umans VA, Cornel JH, Velthoven SS, et al. Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. Int J Cardiovasc Intervent. 1999;2(4):223-230doi: 10.1080/acc.2.4.223.230.
Umans, V. A., Cornel, J. H., Velthoven, S. S., Kloeg, P., Bartels, P., & Bronzwaer, J. (1999). Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. International journal of cardiovascular interventions, 2(4), 223-230. https://doi.org/10.1080/acc.2.4.223.230
Umans, Victor A, et al. "Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic." International journal of cardiovascular interventions vol. 2,4 (1999): 223-230. doi: https://doi.org/10.1080/acc.2.4.223.230
Umans VA, Cornel JH, Velthoven SS, Kloeg P, Bartels P, Bronzwaer J. Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. Int J Cardiovasc Intervent. 1999;2(4):223-230. doi: 10.1080/acc.2.4.223.230. PMID: 12623572.
Copy Download .nbib Format: NLM
The Use of Abciximab in the Treatment of Subacute Stent Thrombosis.

The Journal of invasive cardiology

Rath PC, Panigrahi NK.
PMID: 10762844
J Invasive Cardiol. 1998 Nov;10(9):558-560.

No abstract available.

Cite
Rath PC, Panigrahi NK. The Use of Abciximab in the Treatment of Subacute Stent Thrombosis. J Invasive Cardiol. 1998;10(9):558-560
Rath, P. C., & Panigrahi, N. K. (1998). The Use of Abciximab in the Treatment of Subacute Stent Thrombosis. The Journal of invasive cardiology, 10(9), 558-560.
Rath, and Panigrahi. "The Use of Abciximab in the Treatment of Subacute Stent Thrombosis." The Journal of invasive cardiology vol. 10,9 (1998): 558-560.
Rath PC, Panigrahi NK. The Use of Abciximab in the Treatment of Subacute Stent Thrombosis. J Invasive Cardiol. 1998 Nov;10(9):558-560. PMID: 10762844.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 147 entries